Key result
DMP 728 reduced occlusive thrombus formation compared to controls in a canine model of arterial thrombosis.
Why the study?
Does DMP 728 prevent thrombosis and rethrombosis in a canine model of arterial thrombosis?
Does DMP 728 prevent thrombosis and rethrombosis in a canine model of arterial thrombosis?
DMP 728, a GPIIb/IIIa receptor antagonist, effectively prevents arterial thrombosis and rethrombosis in a canine model.
Answers are grounded in this paper and cite their sources.
Supports GPIIb/IIIa blockade in canine thrombosis; leaves open translation to human arterial disease.
Summary: The platelet glycoprotein IIb/IIIa receptor (GPIIb/IIIa, fibrinogen receptor) represents the final common pathway for platelet aggregation. Inhibition of GPIIb/IIIa with antibodies or peptides containing the RGD sequence has been reported to prevent arterial thrombosis. We examined DMP 728 [(cyclic[d-2-aminobutyryl-N2-methyl-l-arginyl-glycyl-l-aspartyl-3-(aminomethyl-benzoic acid], methanesulfonic acid salt], a cyclic peptidomimetic, GPIIb/IIIa receptor antagonist, for prevention of thrombosis and rethrombosis in a canine model of carotid artery thrombosis. Dogs were anesthetized, and both carotid arteries were instrumented with an electrode, a flow probe, and a stenosis. A 300-μA current was applied to the intimal surface in the right carotid artery (RCA, control) through the electrode; time to occlusive thrombus formation and thrombus mass was noted. The RCA served as the control vessel; the left carotid artery (LCA) served as the test vessel after DMP 728 administration (0.1 or 1.0 mg/kg, intravenously, i.v.). As compared with controls, occlusive thrombus formation was reduced by both doses of DMP 728 (control 100% n = 12; 0.1 mg/kg i.v. 17%, p < 0.05, n = 6; 1.0 mg/kg i.v. 0%, p < 0.05, n = 6), time to occlusion was increased (p < 0.05), and thrombus weight was reduced (p < 0.05). Ex vivo platelet aggregation was inhibited in all groups. In a second group of animals, a carotid artery thrombus was formed and lysed with anisoylated plasminogen activator complex (APSAC; 0.05 U/kg intraarterially, i.a.) with or without DMP 728. Dogs receiving saline demonstrated a 100% rate of rethrombosis as compared with 25% of DMP 728-treated dogs reoccluding after recannalization (p < 0.05). Competition binding analysis showed that DMP 728 can prevent binding of 7E3 GPIIb/IIIa antibody to platelets in vitro. The data suggest that DMP 728 may have therapeutic potential as an effective antithrombotic agent by inhibiting the platelet–fibrinogen interaction representing the final common pathway in platelet-dependent thrombus formation.
No takes yet. Share an insight, caveat, or question.
Rote et al. (1994) studied Arterial thrombosis. DMP 728 vs. Control (untreated vessel or saline) was evaluated on Occlusive thrombus formation (p=<0.05). DMP 728 reduced occlusive thrombus formation compared to controls in a canine model of arterial thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: